R&D

FDA Grants Krystal FTD for KB103

For the treatment of dystrophic epidermolysis bullosa (DEB)

05.24.18

Bio News | Industry News | Methods Development | R&D

Bringing A Molecule to Market

Christian Cattaruzza, Marketing Director of Bioreliance End to End Solutions at MilliporeSigma, shares insight

Videos

Avenue Announces Positive Phase 3 Trial Results

For IV tramadol, for the severe postoperative pain following surgery

05.21.18

Recipharm, Hadasit Enter Partnership

To offer combined clinical, biological and chemical services

05.15.18

Evotec AG, Carna Enter Agreement

Carna will access Evotec's INDiGO platform to accelerate the development of CB-1763, for the treatment of blood cancer

05.14.18

Drug Development | Information Technology | R&D

CRO Industry Update: Big Data Drives Drug Development Efforts

With growth in virtual trials and RWE, the clinical development landscape may never look the same

Kristin Brooks, Managing Editor 05.11.18

Moderna, Merck Expand Partnership

To continue to develop and commercialize novel personalized messenger RNA cancer vaccines

05.10.18

Bio News | Collaborations & Alliances | Drug Development | Industry News | R&D

Protagen, UCSF Enter Collaboration

Using Protagen’s SeroTag to investigate the immuno-profiling of prostate cancer patients treated with checkpoint inhibitors

05.10.18

R&D

A Blueprint to Unify Clinical Operations

Fast-growing clinical research organization speeds study execution and improves quality

Jim Reilly, VP of Clinical Market Strategy, Veeva Systems 05.08.18

Proteon, Lonza Extend Contract

For the commercial supply of investigational vonapanitase’s active pharmaceutical ingredient

05.08.18

Melinta Therapeutics, CARB-X Enter Partnership

Melinta to be awarded up to $6.2M to support the development of the company’s investigational pyrrolocytosine compounds

05.07.18

Aptose To License CG-806 from CrystalGenomics

The move comes after Aptose exercised the option under a 2016 Option Agreement

05.07.18

R&D

Newsmakers: Charles River

Charles River Expands

Kristin Brooks, Managing Editor 05.07.18

Industry News | Promotions & Moves | R&D

Atara Appoints New R&D Head

Dietmar P. Berger, M.D., Ph.D. was most recently a senior vice president at Genentech

05.07.18

Bio News | Drug Development | Drug Discovery | Industry News | R&D

Spinogenix Receives Grant from NIH

To fund research and development of a novel family of compounds to help restore the brain functions lost from AD

05.02.18

Biogen, Neurimmune Amend Agreement

Biogen to make a $50M payment to Neurimmune in exchange for a 5% reduction in the original royalty rates on aducanumab sales

05.01.18

Arena Pharmaceuticals, Outpost Medicine Enter Agreement

To advance an undisclosed, preclinical compound with potential utility in treating genitourinary disorders

05.01.18

Analytical Services | Breaking News | Facilities | Industry News | R&D

Cambrex Continues Expansion Plans with New Lab

Completes $3.2M analytical research and development laboratory at its High Point, NC facility

04.24.18

Q Therapeutics, REPROCELL Form MAGiQ Therapeutics

To treat demyelinating and degenerative diseases of the CNS

04.23.18

Noramco, SPI Pharma Sign Agreement

To develop a set of “value-added” formulation packages for global pharma manufacturers of finished dosage forms

04.23.18

Login

Join

FOLLOW:

Subscribe Free

Magazine

eNewsletter

Checkout

FDA Grants Krystal FTD for KB103

Bringing A Molecule to Market

Avenue Announces Positive Phase 3 Trial Results

Recipharm, Hadasit Enter Partnership

Evotec AG, Carna Enter Agreement

CRO Industry Update: Big Data Drives Drug Development Efforts

Moderna, Merck Expand Partnership

Protagen, UCSF Enter Collaboration

A Blueprint to Unify Clinical Operations

Proteon, Lonza Extend Contract

Melinta Therapeutics, CARB-X Enter Partnership

Aptose To License CG-806 from CrystalGenomics

Newsmakers: Charles River

Atara Appoints New R&D Head

Spinogenix Receives Grant from NIH

Biogen, Neurimmune Amend Agreement

Arena Pharmaceuticals, Outpost Medicine Enter Agreement

Cambrex Continues Expansion Plans with New Lab

Q Therapeutics, REPROCELL Form MAGiQ Therapeutics

Noramco, SPI Pharma Sign Agreement

May 2018